A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Inclusion Criteria:

• Histologically confirmed metastatic or locally advanced unresectable solid tumor.Must have received prior standard therapy.

• Measurable disease per RECIST 1.1

• Eastern Cooperative Oncology Group performance status of 0 or 1

• Adequate baseline laboratory values

• Patients of childbearing potential or those with partners of childbearing potentialmust agree to use a highly effective method of birth control from signing the ICF,and for a period of 30 days after the last dose of CX-904.

• Additional inclusion criteria may apply

Exclusion Criteria:

• History of malignancy that was active within the previous 2 years. Exceptionsinclude localized cancers that are not related to the current cancer being treated,that are considered to have been cured, and in the opinion of the Investigator,present a low risk of recurrence

• Screening electrocardiogram demonstrating a mean QTcF value > 480 msec; a screeningechocardiogram with left ventricular ejection fraction (LVEF) < 50%

• Serious concurrent illness

• History of or current active autoimmune diseases

• History of myocarditis regardless of the cause

• Pregnant or breast feeding

• Additional exclusion criteria may apply